Effects of Automated Adjustment of Inspired Oxygen With Combined Adaptive Mechanical Backup Ventilation as Compared to Automated Oxygen Adjustment Alone in Preterm Infants With Intermittent Hypoxemic Events During Non-invasive Ventilatory Support
NCT ID: NCT02774408
Last Updated: 2016-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
37 participants
INTERVENTIONAL
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Automated Versus Manual Oxygen Control in Preterm Babies on Respiratory Support
NCT06622161
Open Lung Maneuvers During High Frequency Oscillatory Ventilation in Preterm Infants
NCT04289324
Apneic Intubation Critically Ill Children
NCT04890288
The Difference Between Non-invasive High-frequency Oscillatory Ventilation and Non-invasive Continuous Airway Pressure Ventilation in COVID-19 With Acute Hypoxemia
NCT05706467
Different Levels of BiPAP
NCT06421519
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Randomization of the sequence of the two study phases will be carried out using sealed envelopes. Infants will be changed to a specific ventilator device approved for clinical use in neonates in Germany (Sophie®-Respirator, Stephan Medizintechnik GmbH, Gackenbach, Germany), which is capable to automatically adjust the FiO2 (called "SPO2C") and to apply noninvasive backup-ventilation (using a noninvasive trigger device (S-NIPPV) or non-synchronized nasal IPPV (NIPPV) based on readings of an incorporated SpO2 monitoring device (Masimo® Radical 7, averaging time 2 sec). Synchronization of NIPPV and detection of apnea is achieved by using the Graseby capsule (Stephan, Vio Healthcare Ltd, Ref. 103560103), which will be secured onto the anterior abdominal wall near to the right costal margin.
Infants on CPAP (first group) will be exposed to the first study phase (SPO2C, or SPO2C + BU, Figure 1) for 24h and then will be switched to the alternate mode for 24h each. Infants, who are already on nasal IPPV (SIPPV or NIPPV) as chosen by the clinical team will be exposed to NIPPV with a standardized inflation rate of 40 breaths/min (nonsynchronized, because this seems to be the current standard of care according to the available literature) and SPO2C, or to SPO2C plus synchronized BU (starting with a rate of 80 inflations/min with stepwise weaning) and then will be switched to the alternate mode for 24h each.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CPAP
Infants on CPAP will receive backup breafs whenever the SpO2 \<88 % along with
automated FiO2 controller. In the control period they will receive automated FiO2
alone
Saturation sensitive backup ventilation
NIMV/NIPPV
Infants on NIMV NIPPV will receive an increase in the backup rate to 2 times the rate
of the backup triggered by apnoe (apnoe time 5s), whenever the SpO2 under 88%
( max rate 100/min) in the reference period as compared to baseline (automated FiO2
\- control + unchanged SIPPV settings)
Saturation sensitive backup ventilation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saturation sensitive backup ventilation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. on nasal/nasopharyngeal CPAP or nasal IMV / IPPV
3. at least 4 desaturations (SpO2 \<80%) during an 8 hour period within the 24h before the study using a standard pulse oximeter incorporated in the NICU (Masimo SET, Irvine, CA, averaging time 8 sec; delay 10s)
4. informed consent obtained from the parents or legal guardian
Exclusion Criteria
2. congenital cyanotic heart disease
3. no decision for full treatment support
4. Average FiO2 during the last 24h bevor the active study phase \>0.60 (too sick for non-invasive ventilator support)
5. Congenital malformations of the lung or the diaphragm (i.e. diaphragmatic hernia, congenital cystic lung diseases...)
6. Clinical evidence for seizures
7. Ongoing Sepsis with hemodynamic compromise (defined as a CrP \> 20mg/l or positive blood culture (for sepsis), and requirement of catecholamines (for hemodynamic compromise))
8. Need of blood-transfusion during study time
96 Hours
34 Weeks
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. von Hauner Children's Hospital
OTHER
University of Ulm
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Helmut Hummler
Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FiO2 Backup
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.